|
|
|
|
|
19.03.26 - 13:36
|
Niagen Bioscience Increases Share Repurchase Program to $20 Million (Business Wire)
|
|
|
LOS ANGELES--(BUSINESS WIRE)--$NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has authorized an increase to the Company's previously disclosed share repurchase program (the “Program”), raising the total authorization from $10 million to $20 million of the Company's outstanding common stock.
Through March 17, 2026, the Company has repurchased approximately $2.6 million of its common stock under the Share Repurchase Program. Additional information regarding share repurchases will be reported in the Company's periodic reports filed with the SEC.
Rob Fried, CEO, Niagen Bioscience, stated, “The recent repurchase of our common stock and $10 million increase in our program reflect the conviction we have in our strategy and long-term value. We will continue to take advantage of the disconnect between NAGE's market valuation and the underlying ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.03.26 - 22:06
|
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 (Business Wire)
|
|
|
Net sales increased 30% year-over-year to $129.4 million in 2025
Gross margin increased 250 bps year-over-year to 64.3% in 2025
Net income increased 103% year-over-year to $17.4 million in 2025
Adjusted EBITDA increased 139% year-over-year to $20.4 million in 2025
Cash and cash equivalents totaled $64.8 million at December 31, 2025 compared to $44.7 million at December 31, 2024
Full year 2026 net sales outlook reflects between 10-15% growth, excluding the recently sold reference standards segmentLOS ANGELES--(BUSINESS WIRE)--$NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results.
Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter
Total net sales increased 16% to $33.8 million, with Tru Niagen® sales of $27.5 million, up 21% from the prior year quarter.
Gross margin increased 160 basis points to 64.1%.
Net income of $4.1 million compared to $7.2 million in the prior year quarter. Q4 2024 benefited from a $3.5 mil...
|
|
|
06.02.26 - 14:39
|
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026 (Business Wire)
|
|
|
LOS ANGELES--(BUSINESS WIRE)--$NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025, which ended December 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, March 4, 2026.
Investor Conference Call:
Niagen Bioscience management will host an investor conference call to discuss the fourth quarter and fiscal year 2025 financial results and provide a general business update on Wednesday, March 4, 2026, at 4:30 p.m. ET. Participants should call in at least 10 minutes before the call. The dial-in information is as follows:
Date: Wednesday, March 4
Time: 4:30 p.m. ET (1:30 p.m. PT)
Toll-free dial-in number: +1 800 715 9871
Conference ID: 8584242
Webcast ...
|
|
|
|
|
22.12.25 - 14:36
|
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen′s University Belfast (Business Wire)
|
|
|
This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in the NAD+ industryLOS ANGELES--(BUSINESS WIRE)--$NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has acquired a comprehensive portfolio of existing patents covering nicotinamide riboside (NR) and its salt forms from Queen's University Belfast (QUB), further strengthening the Company's long-standing leadership and ownership position in NAD+ precursor intellectual property.
The acquired portfolio comprises the core body of patents underpinning the production, composition, and commercial use of NR, encompassing foundational composition-of-matter patents covering crystal morphologies, methods of making NR and other NAD+ precursors, and global patent rights spanning multiple jurisdictions. Prior to this transaction, Niagen Bioscien...
|
|
|
|
|
|
|
|
|
06.11.25 - 14:12
|
Niagen Bioscience Announces $10 Million Share Repurchase Program (Business Wire)
|
|
|
LOS ANGELES--(BUSINESS WIRE)--$NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has approved a share repurchase program under which the Company is authorized to repurchase up to $10 million of outstanding common stock over approximately 24 months (the “Program”).
“We believe Niagen Bioscience is an excellent investment and the Program is a compelling use of the company's capital presently,” said Rob Fried, Chief Executive Officer of Niagen Bioscience.
Under the Program, Niagen Bioscience may repurchase shares in the open market, through privately negotiated transactions or otherwise, subject to applicable laws and market conditions. The timing, method, pricing, and actual amounts of any repurchases will be determined by management, and there is no obligation to repurchase any shares. The Program may be modified, suspended, or terminated a...
|
|
|
|
|
|
|
04.11.25 - 22:03
|
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook (Business Wire)
|
|
|
Net sales increased 33% to $34.0 million
Gross margin increased 100 bps to 64.5%
Net income of $4.6 million, up $2.7 million from the prior year
Adjusted EBITDA increased by 120% to $6.4 million
Full year 2025 net sales outlook of 25% to 30% year-over-year growth
LOS ANGELES--(BUSINESS WIRE)--$NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the third quarter of 2025.
Third Quarter 2025 Financial Highlights Compared to Prior Year Period
Total net sales increased 33% to $34.0 million, with Tru Niagen® sales of $26.0 million, up 44%.
Gross margin increased 100 basis points to 64.5%.
Sales and marketing expense as a percentage of net sales was 25.8%, an improvement of 170 basis points.
Net income of $4.6 million or $0.06 earnings per share, up from $1.9 million or $0.02 earnings per share, in the prior year quarter.
Adjusted EBITDA, a non-GAAP measure, increased 120% to $6.4 million.
Total cash provided by operations of $12.8 million during the nine months ended Sep...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
